Molecular pathways: Mucins and drug delivery in cancer

Chinthalapally V. Rao, Naveena B. Janakiram, Altaf Mohammed*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Over the past few decades, clinical and preclinical studies have clearly demonstrated the role of mucins in tumor development. It is well established that mucins form a barrier impeding drug access to target sites, leading to cancer chemoresistance. Recently gained knowledge regarding core enzymesynthesis hasopened avenues to explore the possibility of disrupting mucin synthesis to improve drug efficacy. Cancer cells exploit aberrant mucin synthesis to efficiently mask the epithelial cells and ensure survival under hostile tumor microenvironment conditions. However, O-glycan synthesis enzyme core 2 beta 1,6 N-acetylglucosaminyltransferase (GCNT3/C2GnT-2) is overexpressed in Kras-driven mouse and human cancer, and inhibition of GCNT3 has been shown to disrupt mucin synthesis. This previously unrecognized developmental pathway might be responsible for aberrant mucin biosynthesis and chemoresistance. In this Molecular Pathways article, we briefly discuss thepotential role ofmucin synthesis in cancers,ways to improve drug delivery and disrupt mucin mesh to overcome chemoresistance by targeting mucin synthesis, and the unique opportunity to target the GCNT3 pathway for the prevention and treatment of cancers.

Original languageEnglish
Pages (from-to)1373-1378
Number of pages6
JournalClinical Cancer Research
Issue number6
StatePublished - 15 Mar 2017
Externally publishedYes


Dive into the research topics of 'Molecular pathways: Mucins and drug delivery in cancer'. Together they form a unique fingerprint.

Cite this